+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers



Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers



Lupus 9(1): 26-32



Since the mechanism mediating the beneficial effect of intravenous cyclophosphamide (IVCY) in systemic lupus erythematosus (SLE) is unknown, we investigated lymphocyte subsets and markers of activated lymphocytes in patients received IVCY, and compared the results with the effect of steroid pulse. In 55 patients with SLE, 34 patients receiving IVCY (21 cases (61.8%) were responsive) and 25 patients received steroid pulse (21 cases (84.0%) were responsive) (four patients who were resistant to steroid pulse therapy were transferred to IVCY). When the lymphocyte subsets and markers of activated lymphocytes were compared in the responsive and unresponsive group of IVCY, soluble CD4 levels and the ratio of HLA-DP-positive T cells were significantly higher in the unresponsive group. Further, the changes of these markers and costimulatory molecules (LFA-1 (CD11a), ICAM-1 (CD54), CD40 and CD40-ligand (CD154)) were also examined in the responsive patients. The ratio of HLA-DP-positive T cells did not change in the IVCY-responsive group, while it decreased in the steroid pulse therapy-responsive group. The ratio of CD11a on T cells increased and CD54 on B cells decreased in the IVCY-responsive group. The ratio of CD154 on T cells increased in the steroid pulse-responsive group, while it decreased in the IVCY-responsive group. These results suggest that the effect of IVCY is different to that of steroid pulse therapy and mainly related to B cell activation, and that these markers may contribute to predict the responsiveness of IVCY.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010527010

Download citation: RISBibTeXText

PMID: 10713644

DOI: 10.1177/096120330000900106


Related references

Treatment of the diffuse and focal proliferative forms of lupus nephropathy with intravenous cyclophosphamide. Intravenous cyclophosphamide in systemic lupus erythematosus. Revista Clinica Espanola 195(8): 524-529, 1995

Surface activation markers on CD2+ lymphocyte fraction from systemic lupus erythematosus patients. 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY [Author] The 9th International Congress of Immunology : 632, 1995

Immunosuppression in systemic lupus erythematosus. Effect of cyclophosphamide and corticoids on lymphocyte subpopulations. Medicina 39(3): 289-297, 1979

Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Annals of the Rheumatic Diseases 50(12): 956-958, 1991

Regulatory effect of Langchuang serial recipes on T-lymphocyte subsets Th and Tc in patients with systemic lupus erythematosus. Chinese Journal of Integrative Medicine 14(3): 180-184, 2008

High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis and Rheumatism 62(5): 1487-1493, 2010

Protein losing enteropathy and interstitial cystitis due to systemic lupus erythematosus effect of intravenous infusion of cyclophosphamide. Gastroenterologie Clinique et Biologique 14(10): 771-775, 1990

Lymphocyte subsets in systemic lupus erythematosus. Malaysian Journal of Pathology 19(2): 121-125, 2000

Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 10(12): 866-872, 2002

Fluctuating levels of serum soluble Fas in relation to disease activity and lymphocyte activation in systemic lupus erythematosus. Arthritis & Rheumatism 40(9 SUPPL ): S178, Sept, 1997

Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): Relation to lymphocyte activation and disease activity. Lupus 10(12): 866-872, 2001

Lymphocyte subsets in patients with systemic lupus erythematosus. Arthritis and Rheumatism 25(7): 828-832, 1982

T-lymphocyte subsets and platelet count in lupus patients treated by intravenous pulse cyclophosphamide. Nephrology Dialysis Transplantation 7(7): 679, 1992

Abnormalities of lymphocyte subsets in canine systemic lupus erythematosus. Autoimmunity 22(1): 1-8, 1995

Relationship between T lymphocyte subsets and cortisol in systemic lupus erythematosus. Kathmandu University Medical Journal 7(27): 213-219, 2010